• Puromycin Aminonucleoside: From Injury to Insight

  2026-08-18

  Puromycin aminonucleoside is more than a nephrotoxic reagent: it is a controlled perturbation for connecting podocyte architecture, glomerular filtration failure, and proteome-level stress responses. This thought-leadership perspective outlines how to use the aminonucleoside moiety of puromycin strategically in renal disease models while applying emerging solubility-aware proteomics with appropriate translational caution.

• In Vitro Antibacterial Activity of Leucomycin

  2026-08-18

  Iwata and Akiba provided one of the early systematic evaluations of Leucomycin, including its A1 fraction, against clinically relevant bacteria and antibiotic-resistant staphylococci. Their comparative agar, broth, and paper-disc experiments established a broad phenotypic spectrum and created a useful foundation for later macrolide resistance characterization and antibacterial drug discovery.

• Biotin-HPDP for Reliable Thiol Labeling

  2026-08-17

  Learn how Biotin-HPDP (SKU A8008) supports reversible thiol-specific protein labeling, streptavidin-based detection, and orthogonal interpretation of viability or cytotoxicity experiments. This scenario-driven guide covers compatibility, optimization, controls, and practical product-selection criteria.

• ECL Western Blotting Substrate: Practical Guide

  2026-08-17

  ECL Western Blotting Substrate (SKU K2187) is a luminol-based, nonradioactive horseradish peroxidase detection reagent for chemiluminescent immunoblots. It is intended for HRP Western blot workflows using X-ray film or CCD imaging, not for fluorescent or radioisotopic detection, and the prepared solution should be used promptly.

• PR-619: Turning DUB Biology into Translational Insight

  2026-08-16

  PR-619 offers a reversible, broad-spectrum way to perturb deubiquitylating enzymes without directly inhibiting proteasomal catalytic activity. This thought-leadership guide connects mechanism, assay design, physicochemical control, and translational decision-making across cancer biology research, autophagy, and neurodegenerative disease models.

• Lactylation, NSUN2, and Neural Invasion in PDAC

  2026-08-15

  This 2026 Theranostics study identifies NSUN2 K692 lactylation as a metabolic link between lactate accumulation and perineural invasion in pancreatic ductal adenocarcinoma. Integrated clinical, cellular, transcriptomic, and animal-model experiments support a lactate–NSUN2–m5C–CDCP1/STC1 pathway that stabilizes pro-invasive transcripts and may provide mechanistically informed targets for limiting neural spread.

• Separating Growth Arrest from Cell Death in Drug Response

  2026-08-14

  Hannah Schwartz’s dissertation identifies a central interpretive problem in cancer pharmacology: relative viability and fractional viability are often treated as interchangeable even though they capture different biological outcomes. Its framework shows that drug-induced proliferation arrest and cell death can occur in different proportions and on different timelines, supporting more precise evaluation of anticancer responses in vitro.

• SU 5402: Reliable RTK Assay Design

  2026-08-14

  This scenario-based guide explains how SU 5402 (SKU A3843) can clarify receptor tyrosine kinase biology in viability, proliferation, cell-cycle, and apoptosis experiments. It covers stock preparation, assay controls, mechanistic interpretation, and practical vendor-selection criteria without treating biochemical potency as a universal cellular dose.

• Caspase-4 Colorimetric Assay Kit Workflow

  2026-08-13

  Turn pyroptosis and inflammatory signaling questions into a practical, quantitative workflow with LEVD-pNA cleavage and pNA calibration. This guide shows how to distinguish caspase-4 enzyme activity from broader cell-death phenotypes and how to extend the assay to ER-targeted cancer research.

• 2X HyperFusion High-Fidelity Master Mix Guide

  2026-08-13

  2X HyperFusion High-Fidelity Master Mix combines a fusion proofreading polymerase with optimized buffer and dNTP components for high accuracy DNA amplification. Its reported blunt-end product generation, fragment capability up to 10 kb, and rapid extension guidance make it relevant to cloning PCR applications, while the cited cancer-immunotherapy study provides application context rather than direct validation of this reagent.

• Mitocytosis-Targeted Mitochondrial Therapy

  2026-08-12

  Deng and colleagues show that mitocytosis can blunt mitochondria-targeted antimetastatic therapy in migrasome-rich breast tumors. Their hybrid membrane nanoplatform combines mitochondrial damage with integrin-mediated mitocytosis inhibition, providing a mechanistic strategy to improve treatment response in the 4T1 model.

• Lovastatin Workflows for HMG-CoA Reductase Research

  2026-08-12

  Build more informative Lovastatin experiments by connecting cholesterol-pathway inhibition with proliferation, apoptosis, efferocytosis, and fibroblast remodeling assays. This practical guide combines dose planning, formulation controls, quantitative readouts, and a plant-development reference framework without overstating cross-domain evidence.

• Elbasvir–Grazoprevir for HCV: Evidence and Methods

  2026-08-11

  The 2021 review by Wang, Huang, and Yu synthesizes the pharmacology, pharmacokinetics, clinical efficacy, safety, and resistance profile of the fixed-dose elbasvir–grazoprevir regimen. Its central contribution is showing how complementary NS5A and NS3/4A inhibition supports effective treatment of HCV genotype 1 and 4 infections, including clinically complex populations.

• AAPH: Calibrating Lipid Peroxidation Assays

  2026-08-11

  AAPH enables controlled oxidative stress experiments without pretending that every lipid-peroxidation phenotype is ferroptosis. This guide connects AAPH chemistry with the PRDX6–GPX4 defense pathway and shows how to design interpretable erythrocyte, membrane, and antioxidant assays.

• Neuromedin S (rat): Practical GPCR Assay Guide

  2026-08-10

  Neuromedin S (rat) provides a defined rat peptide agonist for controlled neuromedin U receptor signaling and GPCR/G protein signaling workflows. It is intended for scientific research assays and should not be used for diagnosis, therapy, or clinical in vivo applications.

15401 records 1/1027 page Next 12345 下5页 Last page